Upcoming Webinars

Health Equity in HEOR: Past, Present and Future Research Implications
Friday, March 31, 2023
10:00AM EDT | 2:00PM UTC | 4:00PM CEST
Introduction to Open-Source Modeling: R We There Yet?
Wednesday, April 19, 2023
12:00PM EDT | 4:00PM UTC | 6:00PM CEST
Clinical Trial Innovation: How Healthcare Technology is Evolving
Wednesday, May 31, 2023
11:00AM EDT | 3:00PM UTC | 5:00PM CEST
Challenges in Rare Disease Diagnostics: An Overview 
Thursday, June 1, 2023
10:00AM EDT | 2:00PM UTC | 4:00PM CEST

Most Recent


FDA Patient-Focused Drug Development (PFDD) Guidance - Part 2

Mar 2023

In this webinar series, we will hear from patient representatives and FDA staff to learn what is covered in this guidance series and what these new guidances mean for patient-focused drug development and the HEOR community.

Improving Treatment Access and Outcomes by Integrating Social Determinants of Health Data With Real-World Evidence

Feb 2023

This webinar will focus on how integrating social determinants of health (SDOH) data with claims-based research can provide an opportunity to improve treatment access and outcomes for under-represented populations through targeted research and strategic efforts.

Preventing, Detecting, and Analyzing Data From Suspected Fraudulent Respondents in Online Surveys, with Examples From Health Preference Studies

Feb 2023

The workshop will use real-time polling to understand the audience’s experiences with data collection fraud online and the methods used to prevent and identify data collection fraud. We will encourage audience members to share their own strategies, learnings, and challenges.

Digital Endpoint Adoption: the How, What and Why

Feb 2023

Focusing on clinical neurosciences (CNS), and using first-hand experience from a Parkinson’s study, experts from Parexel discuss how to integrate eCOA science and sensor technology into clinical trials.

FDA Patient-Focused Drug Development (PFDD) Guidance - Part 1

Feb 2023

This is part one of a two-part webinar series. The FDA is developing Patient-Focused Drug Development (PFDD) guidance to inform the inclusion of patient experience when developing new medical therapies and products. This is a four-part guidance series, with two final guidances released, a third draft guidance released and a fourth guidance under development.

Achieving Fit for Purpose Data from Wearables for Age-Related Diseases

Jan 2023

An ageing population means an urgent need for better and effective treatment for age-related illnesses. Despite billion-dollar investments for drug development for these conditions, especially neurogenerative diseases, there is a low success rate and it is a slow process.

Clinical Outcomes



Preventing, Detecting, and Analyzing Data From Suspected Fraudulent Respondents in Online Surveys, with Examples From Health Preference Studies

Feb 2023

The workshop will use real-time polling to understand the audience’s experiences with data collection fraud online and the methods used to prevent and identify data collection fraud. We will encourage audience members to share their own strategies, learnings, and challenges.

Achieving Fit for Purpose Data from Wearables for Age-Related Diseases

Jan 2023

An ageing population means an urgent need for better and effective treatment for age-related illnesses. Despite billion-dollar investments for drug development for these conditions, especially neurogenerative diseases, there is a low success rate and it is a slow process.

Souring On SUCRAs: When Treatment Ranking Goes Wrong

Oct 2022

One of the advantages of network meta-analyses (NMA) is the ability to use findings to draw conclusions regarding the best treatment for a given outcome. The Surface-Under-the-Cumulative-Ranking (SUCRA) is the most common method used to rank treatments in Bayesian NMAs, but it is often misinterpreted and misreported. This webinar will explore what the SUCRA is, demonstrate how it can be meaningfully impacted by network composition (even in simple networks), and suggest corrections to common errors in the reporting of SUCRAs.

Clinical Outcome Assessments in the Asia Pacific Region: Strategy & Implementation

Sep 2022

Asia Pacific regional markets, including but not limited to mainland China, Japan, South Korea and Taiwan, play increasingly important roles in global clinical development. Patient-centric endpoints via clinical outcome assessments (COAs) and electronic COAs (eCOAs), are getting more and more attention in clinical research design and execution.


Economic Evaluation



Health Insurance in Africa: Sustainability in Focus

Oct 2022

Many health systems in Africa are generally characterized by high burden of out-of-pocket payment by patients at the point of care and increased exposure of clients to catastrophic health payments. However, there are recent moves by many African countries to improve their health financing systems and institute health insurance in a bid to ensure universal health coverage.

Stakeholder Engagement in Value Assessment

Aug 2022

This is the Second webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams: (1) Funding: what is the relation between health & the economy and how to ensure the long term healthcare system sustainability, (2) Value: what are the value frameworks used by decision makers in LatAm and what is the impact on patient access, (3) Adoption: how to ensure access for the right patient, to the right treatment, at the right time.

Financing Sustainable Healthcare Systems in Latin America

Jul 2022

This is the first webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams.

Distributional Cost-Effectiveness Analysis to Inform Healthcare Decisions

Jun 2022

This webinar will aim to provide an educational opportunity for the ISPOR membership to learn about the methods for conducting distributional cost-effectiveness analysis (DCEA).


Health Technology Assessment



Health Insurance in Africa: Sustainability in Focus

Oct 2022

Many health systems in Africa are generally characterized by high burden of out-of-pocket payment by patients at the point of care and increased exposure of clients to catastrophic health payments. However, there are recent moves by many African countries to improve their health financing systems and institute health insurance in a bid to ensure universal health coverage.

Fit for Local Context? Establishing or Improving Deliberative Processes for HTA

Sep 2022

Deliberative processes for health technology assessment (HTA) are intended to facilitate participatory decision making, using discussion and open dialogue between stakeholders. Increasing attention is being given to deliberative processes, but guidance is lacking for those who wish to design or use them. Health Technology Assessment International (HTAi) and ISPOR initiated a joint task force that developed comprehensive guidance to address this gap. This webinar will be of benefit to all those involved in establishing or improving deliberative processes for HTA in local contexts.

Financing Sustainable Healthcare Systems in Latin America

Jul 2022

This is the first webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams.


Real-World Data & Information Systems


Improving Treatment Access and Outcomes by Integrating Social Determinants of Health Data With Real-World Evidence

Feb 2023

This webinar will focus on how integrating social determinants of health (SDOH) data with claims-based research can provide an opportunity to improve treatment access and outcomes for under-represented populations through targeted research and strategic efforts.

Different HTA Perspectives on Reliably Estimating Treatment Effects

Nov 2022

Real-World evidence (RWE) has recently received increased attention to provide supplementary evidence to support health technology assessment (HTA) submissions, especially as another source of insight into the real-world performance of novel therapeutic products, particularly when traditional randomized controlled trials (RCTs) are impractical or lack generalizability.

Data Privacy and Digital Health: The Manufacturers/Payers Perspective

Jul 2022

The key success factor for digital health implementation is the information sharing across multiple stakeholders engaged in the clinical decision making. The COVID pandemic revealed numerous differences in how individual data are used in the process of the adoption of various digital health solutions in the healthcare systems across the globe.


Patient-Centered Research



FDA Patient-Focused Drug Development (PFDD) Guidance - Part 2

Mar 2023

In this webinar series, we will hear from patient representatives and FDA staff to learn what is covered in this guidance series and what these new guidances mean for patient-focused drug development and the HEOR community.

FDA Patient-Focused Drug Development (PFDD) Guidance - Part 1

Feb 2023

This is part one of a two-part webinar series. The FDA is developing Patient-Focused Drug Development (PFDD) guidance to inform the inclusion of patient experience when developing new medical therapies and products. This is a four-part guidance series, with two final guidances released, a third draft guidance released and a fourth guidance under development.

Looking Beyond Survival Data: Understanding the Value of Non-OS Endpoints in Oncology Reimbursement Decision-Making

Dec 2022

In this webinar, representatives from different stakeholder groups (patients, physicians, health economists and industry) will discuss the value of increasing the use of non-OS endpoints in reimbursement decision-making to their stakeholder groups. Using the example of multiple myeloma, the speakers will discuss how and when non-OS endpoints should be used, to support a future in which assessments of novel therapies are more fit-for-purpose.

Availability and Access to Innovative Therapies in Latin America

Oct 2022

This webinar will focus on discussing how to ensure access for the right patient, to the right treatment, at the right time. We invited Max Newton, Engagement Manager at IQVIA as guest speaker. Max worked on the development of the FIFARMA "Patients Waiting to Access Innovative Therapies (WAIT) Indicator survey"; he also is leading a similar survey in Europe, the "EFPIA WAIT indicator".

Methodical & Statistical Research



Availability and Access to Innovative Therapies in Latin America

Oct 2022

This webinar will focus on discussing how to ensure access for the right patient, to the right treatment, at the right time. We invited Max Newton, Engagement Manager at IQVIA as guest speaker. Max worked on the development of the FIFARMA "Patients Waiting to Access Innovative Therapies (WAIT) Indicator survey"; he also is leading a similar survey in Europe, the "EFPIA WAIT indicator".

Souring On SUCRAs: When Treatment Ranking Goes Wrong

Oct 2022

One of the advantages of network meta-analyses (NMA) is the ability to use findings to draw conclusions regarding the best treatment for a given outcome. The Surface-Under-the-Cumulative-Ranking (SUCRA) is the most common method used to rank treatments in Bayesian NMAs, but it is often misinterpreted and misreported. This webinar will explore what the SUCRA is, demonstrate how it can be meaningfully impacted by network composition (even in simple networks), and suggest corrections to common errors in the reporting of SUCRAs.

Network Meta-Analysis - Special Topics

Sep 2022

The Statistical Methods in Health Economics and Outcome Research Special Interest Group is pleased to present two webinars on Network Meta-Analysis (NMA). The first one is an introduction to NMA by Emma Hawe. The second will cover special topics in NMA by Sofia Dias. Both webinars will be moderated by Gian Luca Di Tanna. The second webinar will feature more advanced content than the first webinar.

Health Policy & Regulatory



Can the Benefits From Biosimilars Be Sustainably Increased? Policy Recommendations for Europe, Middle East and Canada

Oct 2022

Biosimilars offer great potential for the patients, payers and the whole society. However, there exist policy barriers which can hinder this potential. The debate will analyze the challenges and opportunities for biosimilars uptake in Europe, Middle East and Canada.

Health Insurance in Africa: Sustainability in Focus

Oct 2022

Many health systems in Africa are generally characterized by high burden of out-of-pocket payment by patients at the point of care and increased exposure of clients to catastrophic health payments. However, there are recent moves by many African countries to improve their health financing systems and institute health insurance in a bid to ensure universal health coverage.

Availability and Access to Innovative Therapies in Latin America

Oct 2022

This webinar will focus on discussing how to ensure access for the right patient, to the right treatment, at the right time. We invited Max Newton, Engagement Manager at IQVIA as guest speaker. Max worked on the development of the FIFARMA "Patients Waiting to Access Innovative Therapies (WAIT) Indicator survey"; he also is leading a similar survey in Europe, the "EFPIA WAIT indicator".

Study Approaches


Methods Maze: Pointers for Selecting Survival Extrapolation Models for Cancer Immunotherapy

Oct 2020

In this webinar, we will be discussing this issue in relation to cancer immunotherapy. An overview of the survival extrapolation methods which could be used for cancer immunotherapies will be presented along with an assessment of their strengths and limitations. Finally, the presenters will provide attendees with some pointers to help with the selection of appropriate survival extrapolation models for these agents.

Why and How to Use Qualitative Research Methods in Conjunction with Discrete Choice Experiments in Health Care

Jun 2020

This webinar will explore why and how to use qualitative research methods in conjunction with discrete choice experiments in healthcare. Speakers will discuss formative qualitative research for the identification and generation of attributes and levels and qualitative research for testing survey comprehension and decision-making processes.

Adding Depth to Observational Research through Data Linkage

Apr 2020

This webinar will explore the value and challenges of linking administrative claims data to additional data sources in order to provide a more comprehensive look at the patient journey through a disease state. Data linkage types, techniques and best practices will be discussed.


Epidemiology & Public Health


Availability and Access to Innovative Therapies in Latin America

Oct 2022

This webinar will focus on discussing how to ensure access for the right patient, to the right treatment, at the right time. We invited Max Newton, Engagement Manager at IQVIA as guest speaker. Max worked on the development of the FIFARMA "Patients Waiting to Access Innovative Therapies (WAIT) Indicator survey"; he also is leading a similar survey in Europe, the "EFPIA WAIT indicator".

Stakeholder Engagement in Value Assessment

Aug 2022

This is the Second webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams: (1) Funding: what is the relation between health & the economy and how to ensure the long term healthcare system sustainability, (2) Value: what are the value frameworks used by decision makers in LatAm and what is the impact on patient access, (3) Adoption: how to ensure access for the right patient, to the right treatment, at the right time.

Financing Sustainable Healthcare Systems in Latin America

Jul 2022

This is the first webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams.

The Convergence of Synthetic Data and Self-Service Analytics to Create a New RWE Model

May 2022

Real-world evidence has advanced health research over the past two or three decades. The challenges of procuring sufficient, high-quality real-world data, of unlocking the knowledge contained in the data, and of sharing information without compromising patient privacy are ever-present.


Specialized Treatment Areas


Looking Beyond Survival Data: Understanding the Value of Non-OS Endpoints in Oncology Reimbursement Decision-Making

Dec 2022

In this webinar, representatives from different stakeholder groups (patients, physicians, health economists and industry) will discuss the value of increasing the use of non-OS endpoints in reimbursement decision-making to their stakeholder groups. Using the example of multiple myeloma, the speakers will discuss how and when non-OS endpoints should be used, to support a future in which assessments of novel therapies are more fit-for-purpose.

Health Preference Research in the Context of Gene Therapy in Rare Diseases

Sep 2021

During this webinar, the speakers will present their respective studies on gene therapy in Duchenne muscular dystrophy, spinal muscular atrophy (SMA) and hemophilia. They will discuss the importance of the disease context, the qualitative research that influenced attribute selection, the selection of health preference method and design of the health preferences’ tasks, and how the study findings relate to the potential value of gene therapy.

Biosimilars: Market Access Challenges & Opportunities Worldwide

Feb 2021

This webinar will present an insightful exchange on best practices, challenges and opportunities for market access of biosimilars in different regions worldwide.

Biosimilars: Unleashing The Potential For Improved Patient Access And Cost Savings In The United States

Oct 2020

The webinar will present an overview of societal benefits of biosimilars, how these are measured, how the United States (US) and select markets are tracking in attaining these benefits, and potential solutions for advancing the evidence of potential benefits into action.


Specific Diseases & Conditions


Looking Beyond Survival Data: Understanding the Value of Non-OS Endpoints in Oncology Reimbursement Decision-Making

Dec 2022

In this webinar, representatives from different stakeholder groups (patients, physicians, health economists and industry) will discuss the value of increasing the use of non-OS endpoints in reimbursement decision-making to their stakeholder groups. Using the example of multiple myeloma, the speakers will discuss how and when non-OS endpoints should be used, to support a future in which assessments of novel therapies are more fit-for-purpose.

Challenges in Assessing the Clinical and Economic Value of Future Treatments for Alzheimer’s Disease

Feb 2021

This educational webinar will describe factors that affect the assessment of the clinical and economic value of medical innovations, highlight specific issues with relevance to the societal value of treatments for AD, and place these issues in the context of future health technology assessments for AD treatments.

Long Term Value Demonstration in Alzheimer’s Disease: Evidence Needs

Dec 2020

This educational webinar explores some of the key issues relating to long-term evidence needs within the context of HTA in AD and considers what can be done in the short, medium, and long term to address evidence needs.

Value Assessment in Alzheimer's Disease: A Focus on Equity

Nov 2020

This webinar will define how Alzheimer’s disease affects underserved communities; share opportunities to create more equitable, ethical, and inclusive value frameworks; and educate on the community’s role in solving this problem.

Need More Information or Have Questions?

Contact us for more information on ISPOR education and training.

Contact Us

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×